CRISPR & Cas Genes Market Size, Share & Trends Analysis Report By Product & Service (Vector-basedCas, DNA-freeCas, Cell Line Engineering), By Application, By End Use, And Segment Forecasts, 2020 - 2027

Report Overview

The global clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated (Cas) genes market size was valued at USD 1.42 billion in 2019 and is expected to grow at a compound annual growth rate (CAGR) of 16.6% from 2020 to 2027. Technological advancements in the genome editing platform are expected to drive the market at a significant rate. Recently, two new versions of the Cas9 protein: eSpCas9 and SpCas9-HF have been engineered to minimize off-target editing activity without the requirement for two sgRNAs. In addition, accelerated research for novel enzymes, protein, and gRNA engineering, and off-target detection methods is expected to introduce novel techniques. Moreover, introduction of anti-CRISPR proteins will provide new avenues for the market as these proteins can potentially enhance the accuracy of this technology.

Researchers at UC Berkeley and UC San Francisco have developed an anti-CRISPR protein called AcrIIA4. This protein reduces the off-target effects of this technology by four-folds, without reducing the desired on-target gene-editing. A rapid succession of the research papers pertaining to the use of anti-CRISPR proteins for silencing the effect of Cas genes is expected to drive the usage of this technology.

The landscape of gene editing is also booming with many companies using different versions of CRISPR-Cas as well as companies pursuing alternate modalities with specific advantages. This is due to the high rate of fundamental discoveries in basic gene editing. CRISPR-based detection of nucleic acids is considered to be a specific, sensitive, and reliable approach. Moreover, this method requires testing to be done at a constant temperature. This eliminates the requirement of an expensive PCR platform.

An All-In-One Dual CRISPR-Cas12a (AIOD-CRISPR) assay method has been developed by the University of Connecticut Health Center. This method takes just 20 minutes to detect SARS-CoV-2. Similarly, Mammoth Biosciences and Cepheid, Inc., in collaboration with Sherlock Biosciences, have developed detectors for SARS-CoV-2. Therefore, potential applications of these platforms for disease diagnostics are expected to enhance the market growth.

Product & Service Insights

The product segment dominated the market with a revenue share of 78.4% in 2019. Continuous development of engineered enzymes and combination of different enzymes, such as Cas9 and Cas12a, are the key factors for segment growth. This is because engineered enzymes offer more versatility in experiments, and hence is increasingly being adopted by researchers.

In addition, a rise in R&D investments for the utilization of CRISPR platforms and products to develop new therapies is expected to boost segment growth. For instance, Cellectis received a new patent (US10,584,352) from the U.S. Patent and Trademark Office in March 2020. This new patent covers a method of T-cell preparation by using Cas9 technology for immunotherapy.

DNA-free Cas9 is expected to register the fastest CAGR from 2020 to 2027 as the use of DNA-free Cas9 products can help potentially reduce the off-target cutting of DNA. This is expected to influence the adoption of this gene-editing tool in correlation with human diseases and drug development. In addition, applications of DNA-free Cas9 for genome engineering of grapevine, apple protoplasts, rice lettuce, and tobacco are expected to supplement the segment growth.

End-use Insights

The biotechnology and pharmaceutical companies segment accounted for the largest share of almost 52.0% in 2019. Potential clinical applications of CRISPR-Cas9 have encouraged pharmaceutical start-ups to develop products with the help of CRISPR-mediated gene-editing techniques. Moreover, the industry has witnessed mergers between prominent and emerging players with CRISPR-based products and services.

Most of the major players have been reported to adopt this technology to engineer immune cells and blood stem cells as a tool for drug discovery and to create anticancer therapeutics. For instance, in February 2019, Merck received a U.S. patent for an improved genome-editing method. Post this, the company announced that it will continue collaborating with researchers to leverage the potential of the technology across various applications, such as drug development.

The academics and government research institutes segment is expected to expand at the fastest CAGR from 2020 to 2027. This is attributed to accelerated uptake of the technology in university projects and government-based research bodies. For instance, as published in March 2020, researchers at the University of Toronto, Canada, the technology for systematic mapping of genetic interactions and investigation of functions of sizable genomic segments in mammalian cells represent major goals of biomedical research.

Application Insights

The biomedical application segment accounted for the largest revenue share of 91.7% in 2019 owing to increased usage of CRISPR in biomedical research. There is a significant increase in the number of research studies employing this technique for editing genomes of human somatic cells and induced pluripotent stem cells. In addition, introduction of improved delivery systems and implementation of nano-carriers have significantly improved the specificity and efficacy of CRISPR/Cas technology in the biomedical field.

Rise in the adoption of these molecular scissors as an efficient tool for genome engineering in higher eukaryotes is expected to drive the demand. Rising focus on fields like synthetic biology and other existing fields of genetic engineering, such as plant, animal, and cell line engineering, is anticipated to make a significant contribution to the segment growth.

CRISPR has been widely applied in DNA modification of animal genes for the development of biologics. These materials are used in the study of diseases, along with novel drug development applications. CRISPR-Cas9, along with induced pluripotent stem cells (iPSCs), help perform various steps in tissue engineering, such as preparation of donor-specific tissues-based disease models. Thus, emerging areas of intensive investigation pertaining to translational and disease-focused research are contributing to higher revenue generation.

Regional Insights

North America dominated the market with a share of 37.9% in 2019. Several pharmaceutical companies are engaged in the development of novel therapeutics by deploying genome editing protocols, which has significantly contributed to regional market growth. Moreover, from a global market’s perspective, U.S. has the largest number of CRISPR publications and continues to have the largest repository of cited papers.

The Asia Pacific is expected to witness the fastest growth over the forecast period. Factors responsible for this growth include growing popularity of this technology in Asian therapeutics space and on-going clinical trials in the region. On-going research in gene editing tools to expand the scope of this technology for in vivo applications in humans is expected to influence market growth in this region.

China hosts the largest number of clinical trials involving CRISPR technology in the world. In addition, the country holds more than 858 publicly available CRISPR patent applications, especially in agricultural and other industries. Moreover, more than 20 research groups use these molecular tools for crop modification to improve agricultural output in China. These factors are expected to boost the growth of the Asia Pacific market.

Key Companies & Market Share Insights

The market has been characterized by intense competition due to an increased number of products entering clinical trials and rising number of product launches by the players. Competition has increased among the existing players owing to developments in technology and its potential applications. Moreover, the industry has witnessed major mergers & acquisitions, along with a large number of collaborations among the prominent existing and emerging players in the market. These collaborations are intended to enhance the market presence of players, thus expected to drive the market. Some of the prominent players operating in the CRISPR & CRISPR-Associated (Cas) Genes market are:

• CRISPR Therapeutics

• AstraZeneca

• Addgene

• Caribou Biosciences, Inc.

• Cellectis

• Editas Medicine, Inc.

• Egenesis

• F. Hoffmann-La Roche Ltd.

• Horizon Discovery Group Plc

• Genscrip

• Danaher Corporation

• Intellia Therapeutics, Inc.

• Lonza

•  Merck KGaA

• New England BioLabs

• Takara Bio, Inc.

• Synthego

• Mammoth Biosciences

• Inscripta, Inc.

• Cibus

CRISPR & Cas Genes Market Report Scope

Segments Covered in the Report

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2016 to 2027. For the purpose of this study, Grand View Research has segmented the global CRISPR and Cas genes market report on the basis of product and service, application, end use, and region: 

• Product & Service Outlook (Revenue, USD Million, 2016 - 2027)

  • By Product

    • Kits & Enzymes

      • Vector-based Cas

      • DNA-free Cas

    • Libraries

    • Design Tool

    • Antibodies

    • Others

  • By Service

    • Cell Line Engineering

    • gRNA Design

    • Microbial Gene Editing

    • DNA Synthesis

• Application Outlook (Revenue, USD Million, 2016 - 2027)

  • Biomedical

    • Genome Engineering

    • Disease Model Studies

    • Functional Genomics

    • Epigenetics

    • Others

  • Agricultural

• End-use Outlook (Revenue, USD Million, 2016 - 2027)

  • Biotechnology & Pharmaceutical Companies

  • Academics & Government Research Institutes

  • Contract Research Organizations (CROs)

• Regional Outlook (Revenue, USD Million, 2016 - 2027)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • France

    • U.K.

    • Italy

    • Spain

  • Asia Pacific

    • Japan

    • China

    • South Korea

  • Latin America

    • Brazil

    • Mexico

  • Middle East and Africa (MEA)

    • South Africa

    • Saudi Arabia